Outcome | Symptoms | Number of the patients |
---|---|---|
Completed BCG therapy without any adverse effects | No symptoms | 42 (28.2%) |
Completed BCG therapy with mild adverse effects | Mild irritative voiding symptoms, mild haematuria, fever < 38.5 °C | 33 (22.14%) |
Completed BCG therapy with dose reduction | Severe irritative voiding symptoms, haematuria, or symptoms lasting > 48 h | 21 (14.1%) |
Stopped BCG due to | ||
 1. Adverse effects (moderate/severe) | Allergic Reactions (Joint Pain, Rash) | 23 (15.4%) |
Organ Involvement (Epididymis, Liver, Lung, Kidney, Bone, Joint, Prostate) | Â | |
 2. Disease progression | Tumour is progressing | 10 (6.7%) |
 3. BCG refractory disease | Tumour is present at 3 months, CIS is present at both 3 and 6 months | 7 (4.6%) |
 4. Recurrence during BCG | Tumour recurrence after initial response | 5 (3.3%) |
 5. Patients’ not willing for BCG continuation |  | 8 (5.3%) |